The results emphasize that starting the GLP-1 therapy early, within the first year of a cirrhosis diagnosis, can help provide substantial protection against further MASH cirrhosis decompensations and decrease liver transplantation risk. During a question-and-answer session at the meeting, an attendee asked Dr
Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides
Conflict of interest SH reports being supported by a grant from the NIH and Office of Dietary Supplements (R01HL103866)
This careful selection helps minimize risks and ensures that the benefits of treatment outweigh the potential harms
